Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Teleflex Incorporated
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
The US FDA has announced a high-risk class I recall on a cardiac catheter from Teleflex Inc. subsidiary Arrow International due to the risk of tip damage during use.
The US Medicare agency's new rule for facility fees brings more bad news for Glaukos; Wells Fargo downgrades company’s stock in response.
The US Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes new reimbursement levels for multiple medical devices, including the Glaukos iStent.
- Medical Devices
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Arrow International
- Eon Surgical Ltd
- Hotspur Technologies
- Essential Medical, Inc.
- Hudson Respiratory Care, Inc.
- LMA International N.V.
- NeoTract, Inc.
- Nostix, LLC
- Pyng Medical Corporation
- Semprus BioSciences
- Standard Bariatrics, Inc.
- Ultimate Medical
- Vascular Solutions
- Vasonova Inc.
- Vidacare Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.